- Conditions
- Hippel-Lindau Disease, Kidney Cancer
- Interventions
- 17 allylamino-17-demethoxygeldanamycin, 18 FDG (Fludeoxyglucose 18F), [15-O] H2O, EPL diluent
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 649–672
of 6,440
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Kidney Cancer, Melanoma (Skin), Metastatic Cancer
- Interventions
- sunitinib malate
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- Technetium Tc 99m EC20
- Drug
- Lead sponsor
- Endocyte
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Houston, Texas
- Conditions
- Chronic Kidney Disease
- Interventions
- Chronic Kidney Disease Education
- Behavioral
- Lead sponsor
- East Carolina University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,257 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- Cancer
- Interventions
- anti-thymocyte globulin, rituximab, clofarabine, stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Metastatic Cancer, Metastatic Melanoma, Metastatic Renal Cancer
- Interventions
- Fludarabine, Cyclophosphamide, IL-12 & Anti-NY ESO1 TCR PBL
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Nephrolithiasis
- Interventions
- Fexofenadine Hcl 180Mg Tab, Placebo
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Kidney Disease, Liver Transplantation
- Interventions
- Not listed
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Renal Cell Carcinoma
- Interventions
- Pexastimogene Devacirepvec (Pexa-Vec), Cemiplimab
- Biological
- Lead sponsor
- SillaJen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 5
- States / cities
- Irvine, California • Miami, Florida • St Louis, Missouri + 2 more
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
- Interventions
- filgrastim, carboplatin, doxorubicin hydrochloride, gemcitabine hydrochloride, paclitaxel
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2007
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Tumor
- Interventions
- belinostat, 5-Fluorouracil (5-FU)
- Drug
- Lead sponsor
- Valerio Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire
- Conditions
- Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury (AKI)
- Interventions
- Prismocitrate 18, PrisMax System Version 3.x with calcium line accessory
- Drug · Device
- Lead sponsor
- Vantive Health LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Los Angeles, California • Miami, Florida + 10 more
- Conditions
- Chronic Kidney Diseases, Type2Diabetes
- Interventions
- Alert-based computerized decision support
- Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
- Interventions
- Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration, Relatlimab
- Procedure · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 992 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 495
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 374 more
- Conditions
- End Stage Renal Disease, Hepatitis C Infection
- Interventions
- Affinity plasmapheresis
- Device
- Lead sponsor
- Aethlon Medical Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Kidney Stones
- Interventions
- LithoSpace Extracorporeal Shockwave Lithotripter
- Device
- Lead sponsor
- Advance Shockwave Technology GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Garden City, New York • New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- Galinpepimut-S, GM-CSF, Montanide, lenalidomide, bortezomib
- Biological · Other · Drug
- Lead sponsor
- Sellas Life Sciences Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Kidney Disease
- Interventions
- Nitrate-rich beetroot juice, Nitrate-depleted beetroot juice
- Dietary Supplement
- Lead sponsor
- University of Colorado, Boulder
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Boulder, Colorado
- Conditions
- Kidney Diseases, End Stage Renal Disease
- Interventions
- Ixazomib Oral Capsule
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Cutaneous Squamous Cell Carcinoma, Skin Cancer
- Interventions
- Cosibelimab, Prednisone, Sirolimus, Everolimus
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), CKD Stage 3, CKD Stage 4, CKD Stage 5, Diabetes Mellitus, Diabetic Kidney Disease
- Interventions
- PLAFOND diet
- Dietary Supplement
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Orange, California • Torrance, California
- Conditions
- Kidney Transplant; Complications, Metabolic Acidosis
- Interventions
- Sodium Bicarbonate, Placebo
- Drug · Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Membranous Nephropathy
- Interventions
- ManNAc
- Drug
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- 18 Years to 115 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Solid Tumors, Metastatic Renal Cell Carcinoma
- Interventions
- Part 1: M8891
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 7
- States / cities
- New Haven, Connecticut • Indianapolis, Indiana • Baltimore, Maryland + 4 more